Cargando…

Cardiac FGF23 expression correlates with left ventricular hypertrophy in patients with chronic kidney disease

Detalles Bibliográficos
Autores principales:	Leifheit-Nestler, Maren, Siemer, Robert Große, Flasbart, Kathrin, Fischer, Dagmar-Christiane, Klintschar, Michael, Becker, Jan U, Aufricht, Christoph, Seeman, Tomas, Haffner, Dieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715099/ http://dx.doi.org/10.1186/2194-7791-1-S1-A25

Ejemplares similares

FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis
por: Böckmann, Ineke, et al.
Publicado: (2019)

Paracrine Effects of FGF23 on the Heart
por: Leifheit-Nestler, Maren, et al.
Publicado: (2018)

How FGF23 shapes multiple organs in chronic kidney disease
por: Leifheit-Nestler, Maren, et al.
Publicado: (2021)

FGF23 and Phosphate–Cardiovascular Toxins in CKD
por: Vogt, Isabel, et al.
Publicado: (2019)

Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease—A Pediatric Perspective
por: Grund, Andrea, et al.
Publicado: (2021)

Cardiac Fibroblast Growth Factor 23 Excess Does Not Induce Left Ventricular Hypertrophy in Healthy Mice
por: Leifheit-Nestler, Maren, et al.
Publicado: (2021)

Comprehensive Expression Analysis of Cardiac Fibroblast Growth Factor 23 in Health and Pressure-induced Cardiac Hypertrophy
por: Eitner, Fiona, et al.
Publicado: (2022)

Renal effects of growth hormone in health and in kidney disease
por: Haffner, Dieter, et al.
Publicado: (2021)

Muscle and Bone Impairment in Infantile Nephropathic Cystinosis: New Concepts
por: Haffner, Dieter, et al.
Publicado: (2022)

Rickets guidance: part II—management
por: Haffner, Dieter, et al.
Publicado: (2022)

Rickets guidance: part I—diagnostic workup
por: Haffner, Dieter, et al.
Publicado: (2021)

FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
por: Grabner, Alexander, et al.
Publicado: (2017)

Impact of Altered Mineral Metabolism on Pathological Cardiac Remodeling in Elevated Fibroblast Growth Factor 23
por: Leifheit-Nestler, Maren, et al.
Publicado: (2018)

Importance of leptin signaling and signal transducer and activator of transcription-3 activation in mediating the cardiac hypertrophy associated with obesity
por: Leifheit-Nestler, Maren, et al.
Publicado: (2013)

DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease
por: Dussold, Corey, et al.
Publicado: (2019)

Indoxyl sulfate induces left ventricular hypertrophy via the AhR-FGF23-FGFR4 signaling pathway
por: Kishimoto, Hiroshi, et al.
Publicado: (2023)

FGF23 and its role in X-linked hypophosphatemia-related morbidity
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2019)

In-center Nocturnal Hemodialysis Reduced the Circulating FGF23, Left Ventricular Hypertrophy, and All-Cause Mortality: A Retrospective Cohort Study
por: Kang, Meizi, et al.
Publicado: (2022)

Expression of circulating micro-RNAs in hypertensive patients with left ventricular hypertrophy
por: Zi Ling, Soh, et al.
Publicado: (2012)

The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis
por: Dörr, Katharina, et al.
Publicado: (2022)

Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload
por: Slavic, Svetlana, et al.
Publicado: (2017)

Tissue-Wide Expression of Genes Related to Vitamin D Metabolism and FGF23 Signaling following Variable Phosphorus Intake in Pigs
por: Hasan, Maruf, et al.
Publicado: (2022)

Phosphate and FGF-23
por: Jüppner, Harald
Publicado: (2011)

FGF23 and inflammation
por: Sharaf El Din, Usama A A, et al.
Publicado: (2017)

Editorial: Mineral and Bone Disorder in CKD
por: Printza, Nikoleta, et al.
Publicado: (2022)

Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy
por: Okamoto, Kohei, et al.
Publicado: (2021)

High FGF23 Levels Failed to Predict Cardiac Hypertrophy in Animal Models of Hyperphosphatemia and Chronic Renal Failure
por: Moench, Ian, et al.
Publicado: (2021)

Erratum to: Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy
Publicado: (2022)

FGF-23 in bone biology
por: Wesseling-Perry, Katherine
Publicado: (2009)

FGF23, Biomarker or Target?
por: Rodelo-Haad, Cristian, et al.
Publicado: (2019)

Pleiotropic Actions of FGF23
por: Erben, Reinhold G.
Publicado: (2017)

Selective blood sampling for FGF-23 in tumor-induced osteomalacia
por: Schober, Hans-Christof, et al.
Publicado: (2017)

Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants
por: Enlund-Cerullo, Maria, et al.
Publicado: (2023)

Fibrocystin in MDCK cells: impact on cell adhesion and epithelial morphogenesis
por: Sötje, Birga, et al.
Publicado: (2015)

cGMP and cardiac hypertrophy
por: Perera, Ruwan K, et al.
Publicado: (2015)

Diagnosis and management of mineral and bone disorders in infants with CKD: clinical practice points from the ESPN CKD-MBD and Dialysis working groups and the Pediatric Renal Nutrition Taskforce
por: Bacchetta, Justine, et al.
Publicado: (2023)

FGF23 Producing Mesenchymal Tumor
por: Papierska, Lucyna, et al.
Publicado: (2014)

FGF23 as a calciotropic hormone
por: Rodríguez-Ortiz, María E., et al.
Publicado: (2015)

FGF23 in Acute and Chronic Illness
por: Schnedl, Christian, et al.
Publicado: (2015)

Role of FGF23 in Pediatric Hypercalciuria
por: Moreira Guimarães Penido, Maria Goretti, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8eqbc509a3hj7jbo01tebphoks